ZBP1 (Z-DNA Binding Protein 1)

ZBP1 (Z-DNA Binding Protein 1)

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ZBP1 (Z-DNA Binding Protein 1)</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ZBP1</td>
</tr>
<tr>
<td class="label">Official Name</td>
<td>Z-DNA Binding Protein 1</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>DAI, DLM-1, CMTM4</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>6p24.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>23073</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9H171</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000185730</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>~3.8 kb</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>429 amino acids (full-length human isoform)</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Description</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>CNS-penetrant inhibitors of the ZBP1 pathway are required</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>ZBP1 is involved in antiviral defense; complete inhibition could increase infection risk</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>ZBP1 pathway activation may vary across disease stages; optimal intervention timing is uncertain</td>
</tr>
<tr>
<td class="label">Cell-type specificity</td>
<td>Targeting ZBP1 in specific cell t

ZBP1 (Z-DNA Binding Protein 1)

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ZBP1 (Z-DNA Binding Protein 1)</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ZBP1</td>
</tr>
<tr>
<td class="label">Official Name</td>
<td>Z-DNA Binding Protein 1</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>DAI, DLM-1, CMTM4</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>6p24.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>23073</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9H171</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000185730</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>~3.8 kb</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>429 amino acids (full-length human isoform)</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Description</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>CNS-penetrant inhibitors of the ZBP1 pathway are required</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>ZBP1 is involved in antiviral defense; complete inhibition could increase infection risk</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>ZBP1 pathway activation may vary across disease stages; optimal intervention timing is uncertain</td>
</tr>
<tr>
<td class="label">Cell-type specificity</td>
<td>Targeting ZBP1 in specific cell types (neurons vs. microglia) may be critical</td>
</tr>
<tr>
<td class="label">Biomarkers</td>
<td>Lack of established biomarkers for ZBP1 pathway activity in patients</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Year</td>
</tr>
<tr>
<td class="label">Takaoka et al.</td>
<td>2007</td>
</tr>
<tr>
<td class="label">Kuriakose et al.</td>
<td>2023</td>
</tr>
<tr>
<td class="label">Kim et al.</td>
<td>2020</td>
</tr>
<tr>
<td class="label">He et al.</td>
<td>2021</td>
</tr>
<tr>
<td class="label">Wang et al.</td>
<td>2022</td>
</tr>
<tr>
<td class="label">Hennessy et al.</td>
<td>2023</td>
</tr>
<tr>
<td class="label">Zhang et al.</td>
<td>2022</td>
</tr>
<tr>
<td class="label">Yamaguchi et al.</td>
<td>2023</td>
</tr>
<tr>
<td class="label">Liu et al.</td>
<td>2024</td>
</tr>
<tr>
<td class="label">Kwon et al.</td>
<td>2024</td>
</tr>
<tr>
<td class="label">Chang et al.</td>
<td>2024</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">239 edges</a></td>
</tr>
</table>

ZBP1 (Z-DNA Binding Protein 1), also known as DAI (DNA-dependent Activator of IRFs) or DLM-1, is a cytosolic nucleic acid sensor that plays critical roles in innate immune responses, regulated cell death pathways, and inflammation[@takaoka2007; @kuriakose2023]. Originally identified as a direct sensor of B-form DNA that activates IRF3-mediated antiviral responses, ZBP1 has since been recognized as a master regulator of Z-form nucleic acid sensing, cell death execution, and inflammatory signaling. Importantly, emerging evidence positions ZBP1 as a significant contributor to the pathogenesis of neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS), and [frontotemporal dementia](/diseases/frontotemporal-dementia) (FTD)[@wang2022; @hennessy2023; @zhang2022; @yamaguchi2023].

The protein contains multiple Z-DNA binding domains (Zα) that specifically recognize the left-handed Z-DNA and Z-RNA conformations, distinct from the canonical B-form DNA that predominates in the genome. This unique recognition allows ZBP1 to sense unusual nucleic acid structures — including those formed during viral infections, cellular stress, and potentially in neurodegenerative protein aggregates — and initiate downstream signaling cascades that can be either protective or pathogenic depending on context[@kim2020; @de2023].

Gene and Protein Structure

Gene Information

Protein Domain Architecture

ZBP1 is a multi-domain protein characterized by several distinct structural regions[@kim2020; @kuriakose2023; @de2023]:

Zα domains (N-terminal, two copies): Each Zα domain (~67 amino acids) adopts a characteristic left-handed beta-helix (LβH) fold that specifically recognizes the Z-DNA conformation. The two Zα domains (Zα1 and Zα2) are connected by a short linker and can bind Z-DNA cooperatively. The Zα domains show structural similarity to the Zα domain of [ADAR1](/entities/adar1), and their binding to Z-form nucleic acids is critical for ZBP1 activation in various contexts.

Zβ domain: Some ZBP1 isoforms contain a related Zβ domain that may contribute to nucleic acid binding specificity.

RHIM domain (RIP Homotypic Interaction Motif): Located in the central region of the protein, the RHIM domain is critical for interactions with RIPK1, RIPK3, and ZBP1 itself. The RHIM consists of a short tetrapeptide core sequence (typically (V/I)X(Q/V)L) that mediates homotypic interactions between RHIM-containing proteins. This domain is the key structural element enabling ZBP1's pro-death signaling functions.

C-terminal domain: Contains additional protein-protein interaction motifs involved in downstream signaling. The C-terminal region varies between species and isoforms, contributing to functional diversity.

Structural Basis for Z-DNA Recognition

The crystal structure of the ZBP1 Zα domain bound to Z-DNA reveals the molecular basis for specific Z-form recognition[@kim2020]:

• The Zα domain wraps around the Z-DNA backbone, making extensive contacts with the phosphate-sugar backbone
• Key hydrophobic residues (e.g., Leu175, Phe178, Trp195) insert into the Z-DNA zigzag groove
• Specific hydrogen bonds recognize the Z-DNA-specific backbone conformation (syn-anti alternation of bases)
• The left-handed helix creates a unique surface geometry that the Zα domain complements perfectly
• This high-affinity interaction (KD ~10-100 nM for Z-DNA vs. weak B-DNA binding) enables ZBP1 to distinguish Z-form from B-form nucleic acids in vivo

Normal Physiological Function

DNA Sensing and Innate Immunity

ZBP1 functions as a cytosolic DNA sensor that triggers antiviral immune responses through multiple pathways[@takaoka2007; @mukherjee2023]:

IRF activation: ZBP1 activates IRF3 and IRF7 through interactions with TBK1 and IKK complexes, leading to production of type I interferons (IFN-α/β) — the cornerstone of antiviral immunity.

NF-κB activation: Through associations with RIPK1 and the IKK complex, ZBP1 induces pro-inflammatory gene expression, including cytokines, chemokines, and adhesion molecules[@wang2022].

Inflammasome activation: ZBP1 can directly activate the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) through interactions with ASC and caspase-1, leading to maturation and release of IL-1β and IL-18[@he2021].

Regulation of Cell Death

ZBP1 is a central regulator of [necroptosis](/entities/necroptosis) — a form of programmed inflammatory cell death distinct from [apoptosis](/entities/apoptosis)[@liu2024; @sun2023; @kuriakose2023]:

Necroptosis induction mechanism: Through its RHIM domain, ZBP1 recruits and activates RIPK3 via homotypic RHIM-RHIM interactions. Activated RIPK3 phosphorylates MLKL (Mixed Lineage Kinase Domain-Like), which then oligomerizes and executes membrane rupture — the hallmark of necroptotic cell death.

Pan-caspase inhibition resistance: ZBP1-mediated necroptosis can proceed even when caspases are inhibited (e.g., by z-VAD-fmk), making it particularly relevant in contexts where apoptotic pathways are blocked.

Viral pathogenesis: Many viruses encode RHIM domain-containing proteins (e.g., viral MLKLs, viral M45 proteins) that inhibit ZBP1 or RIPK3 signaling, highlighting the importance of this pathway in host defense.

Physiological roles: Necroptosis participates in development, tissue homeostasis, and pathogen defense. However, dysregulated necroptosis contributes to inflammatory and degenerative diseases.

Z-RNA Recognition

Beyond Z-DNA, ZBP1 can bind to Z-RNA — a left-handed helical RNA conformation formed by certain viral genomes, cellular transcripts (particularly those with alternating purine-pyrimidine sequences), and possibly stress-induced RNA structures[@kim2020; @yang2024; @de2023]. This expanded ligand specificity positions ZBP1 as a general sensor of unusual nucleic acid conformations.

Interaction with ADAR1

The interplay between ZBP1 and [ADAR1](/entities/adar1) is a key regulatory axis in Z-nucleic acid biology[@yang2024; @de2023; @ji2022]:

• ADAR1 editing: ADAR1 (adenosine deaminase acting on RNA 1) edits adenosine to inosine (A-to-I editing) in Z-RNA structures, reducing their ability to activate ZBP1
• ADAR1 deficiency: Loss of ADAR1 function leads to ZBP1 hyperactivation, autoinflammation, and embryonic lethality in mice — rescued by ZBP1 deletion
• Therapeutic relevance: ADAR1 acts as a "brake" on ZBP1 activation; modulating ADAR1 activity could influence ZBP1-driven pathology

ZBP1 in Development

ZBP1-deficient mice are viable and fertile under normal conditions, indicating that ZBP1 is largely dispensible for development. However, ZBP1 becomes critical under conditions of stress, infection, or disease, where it mediates inflammatory and cell death responses.

Role in Neurodegenerative Diseases

Alzheimer's Disease

ZBP1 contributes to AD pathogenesis through multiple interconnected mechanisms[@hennessy2023; @wang2022; @sun2023]:

Amyloid-beta-Induced Activation

Evidence from Hennessy et al. (2023) demonstrates that [amyloid-beta](/proteins/amyloid-beta) (Aβ) aggregates directly activate ZBP1, linking Aβ pathology to innate immune signaling[@hennessy2023]:

Mechanism: Aβ aggregates form Z-form nucleic acid structures that are recognized by the Zα domains of ZBP1. Alternatively, Aβ-induced cellular stress generates Z-RNA species that activate ZBP1.

Inflammasome activation: ZBP1 activation by Aβ triggers the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) in [microglia](/cell-types/microglia-neuroinflammation) and possibly [astrocytes](/entities/astrocytes), leading to caspase-1 activation and IL-1β release.

Neuroinflammation: ZBP1-driven inflammasome activation contributes to the chronic neuroinflammation characteristic of AD, creating a feedforward loop of amyloid pathology and glial activation.

Neuroinflammation and Cell Death

ZBP1-mediated necroptosis and pyroptosis contribute to neuronal loss in AD[@sun2023; @wang2022]:

• Necroptotic neuronal death: ZBP1-RIPK3-MLKL axis activation leads to necroptotic death of [neurons](/entities/neurons), particularly in regions vulnerable to neurodegeneration (hippocampus, cortex)
• Pyroptosis: ZBP1 can also activate pyroptosis (caspase-1-dependent inflammatory cell death) through NLRP3 inflammasome engagement
• PANoptosis: ZBP1 is increasingly recognized as an organizer of PANoptosis — a inflammatory programmed cell death modality that combines features of necroptosis, pyroptosis, and apoptosis[@kwon2024; @phan2024]

Connection to Tau Pathology

While less directly studied, ZBP1 may interact with [tau protein](/proteins/tau) pathology:

• Stress granule associations: Tau pathology and ZBP1 may converge on stress granule biology, where Z-form nucleic acids accumulate
• Microglial activation: ZBP1-mediated neuroinflammation could accelerate tau hyperphosphorylation and aggregation

Parkinson's Disease

ZBP1 involvement in PD centers on dopaminergic [neurons](/entities/neurons), [α-synuclein](/proteins/alpha-synuclein) aggregation, and neuroinflammation[@zhang2022; @wang2022; @sun2023]:

Dopaminergic Neuron Vulnerability

ZBP1 expression is elevated in dopaminergic neurons in PD models and human PD brain tissue[@zhang2022]:

• Expression changes: Studies in MPTP-treated mice and α-synuclein transgenic models show increased ZBP1 expression in substantia nigra pars compacta neurons
• Mitochondrial stress connection: ZBP1 may be activated by mitochondrial DNA released into the cytosol during PD-related mitochondrial dysfunction
• Neuronal death: ZBP1-driven necroptosis contributes to dopaminergic neuron loss in animal models

Alpha-synuclein Pathology

ZBP1 may be activated by [α-synuclein](/proteins/alpha-synuclein) aggregates[@kuriakose2023]:

• Aggregate sensing: α-synuclein fibrils and oligomers may generate or recruit Z-form nucleic acids that activate ZBP1
• Feedforward inflammation: ZBP1 activation in microglia and astrocytes amplifies neuroinflammation, which in turn accelerates α-synuclein aggregation
• Lewy body formation: The inflammatory environment created by ZBP1 signaling may promote the spreading and seeding of α-synuclein pathology

Neuroinflammation

ZBP1-mediated inflammasome activation in [microglia](/cell-types/microglia-neuroinflammation) creates a chronic inflammatory milieu that damages dopaminergic neurons:

• Microglial activation: ZBP1 drives pro-inflammatory activation of microglia through NLRP3 and type I interferon pathways
• Neurotoxic environment: Inflammatory cytokines (IL-1β, TNF-α, IL-6) released by ZBP1-activated glia are toxic to dopaminergic neurons
• Blood-brain barrier dysfunction: ZBP1-driven inflammation may compromise BBB integrity, allowing peripheral immune cell infiltration

Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

ZBP1 has emerged as a significant player in the [ALS/FTD spectrum](/diseases/amyotrophic-lateral-sclerosis)[@yamaguchi2023; @tanaka2023; @phan2024]:

TDP-43 Pathology Connection

ZBP1 is directly linked to [TDP-43 proteinopathy](/mechanisms/tdp-43-proteinopathy), the hallmark pathological finding in ALS, FTD, and many cases of AD[@yamaguchi2023; @tanaka2023]:

• TDP-43 aggregate sensing: Abnormal TDP-43 aggregates may generate Z-form nucleic acid species that activate ZBP1
• Mutual activation: ZBP1 activation can promote TDP-43 aggregation through stress granule pathways and vice versa
• RNA granule dysfunction: Both ZBP1 and TDP-43 participate in RNA granule biology, creating potential intersections in disease mechanisms

Motor Neuron Death

ZBP1-mediated necroptosis contributes to non-cell-autonomous toxicity in ALS[@liu2024; @sun2023]:

• Motor neuron vulnerability: Motor neurons appear particularly susceptible to ZBP1-driven cell death pathways
• Glial contribution: [Astrocytes](/entities/astrocytes) and [microglia](/cell-types/microglia-neuroinflammation) activated through ZBP1 pathways release toxic factors that damage motor neurons
• Inflammatory cell death: PANoptosis and necroptosis in motor neurons and glia drive progressive neurodegeneration

FTD/ALS Spectrum Disorders

The TDP-43 pathology that links ALS and FTD creates a common substrate for ZBP1 involvement[@phan2024; @tanaka2023]:

• Shared TDP-43 pathology: Both conditions feature TDP-43 aggregation and nuclear loss
• RNA dysregulation: ZBP1 and TDP-43 intersect in RNA metabolism and stress granule pathways
• Therapeutic targeting: The ZBP1-TDP-43 axis represents a potential therapeutic target for the entire ALS-FTD spectrum

Traumatic Brain Injury and Secondary Neurodegeneration

ZBP1 contributes to secondary injury mechanisms following [traumatic brain injury](/diseases/traumatic-brain-injury) (TBI)[@yang2022; @sun2023]:

• Acute activation: TBI triggers ZBP1 activation through cellular damage and nucleic acid release
• Neuroinflammation: ZBP1-mediated inflammation drives secondary neuronal damage in the hours to days following injury
• Chronic neurodegeneration: ZBP1 activation may contribute to the development of chronic traumatic encephalopathy (CTE) and post-traumatic neurodegenerative disease

Molecular Mechanisms of ZBP1 in Neurodegeneration

The ZBP1 PANoptosome

ZBP1 functions as an organizing hub for the PANoptosome — a multi-protein complex that coordinates inflammatory cell death[@kwon2024; @phan2024; @liu2023]:

PANoptosome composition: The ZBP1 PANoptosome includes ZBP1 itself, RIPK1, RIPK3, ASC, NLRP3, caspase-1, caspase-8, and potentially other cell death effectors.

Functional outcomes: The PANoptosome can simultaneously activate necroptosis (via MLKL), pyroptosis (via caspase-1), and apoptosis (via caspase-8), creating an inflammatory cell death response that is greater than the sum of individual pathways.

Neurodegenerative relevance: PANoptosis in neurons and glia contributes to the chronic neuroinflammation and progressive cell loss seen in AD, PD, and ALS. Targeting PANoptosome components may be more effective than targeting individual pathways.

ZBP1 and Stress Granules

Stress granules are membraneless organelles that form when translation initiation is inhibited during cellular stress. ZBP1 localization and function intersect with stress granule biology:

• ZBP1 recruitment to stress granules: ZBP1 can be recruited to stress granules under certain conditions, where it may sense Z-form nucleic acids within these structures
• Competition with TDP-43: Both ZBP1 and TDP-43 are RNA-binding proteins that localize to stress granules; their interactions may influence disease progression
• Liquid-liquid phase separation: The formation of ZBP1-containing biomolecular condensates may be relevant to its activation mechanism

Type I Interferon Signaling

ZBP1 activation triggers type I interferon (IFN) responses in the brain[@wang2022; @kuriakose2023]:

• IFN production: ZBP1 activation in neurons and glia leads to production of IFN-β
• Neurotoxicity: Chronic type I interferon signaling is increasingly recognized as neurotoxic and may contribute to neurodegeneration
• Microglial activation: IFN-β activates microglia, promoting a pro-inflammatory, neurotoxic phenotype

Therapeutic Implications

ZBP1 represents a promising therapeutic target for neurodegenerative diseases[@liu2023; @chang2024; @phan2024]:

Targeting Strategies

Small molecule inhibitors: Several approaches are being developed:

• RIPK3 inhibitors: RIPK3 is a downstream effector of ZBP1; inhibitors (e.g., GSK'843, GSK'872) block ZBP1-mediated necroptosis
• MLKL inhibitors: Blocking the executioner of necroptosis prevents downstream cell death
• Direct ZBP1 inhibitors: Novel compounds targeting ZBP1 directly are in discovery
• NLRP3 inhibitors: MCC940, dapansutrile, and other NLRP3 inhibitors block ZBP1-driven inflammasome activation

• ZBP1 knockdown: ASO or siRNA approaches to reduce ZBP1 expression in the CNS
• Gene editing: CRISPR-based approaches to disrupt ZBP1 or its interacting partners

• ADAR1 modulation: Enhancing ADAR1 activity could reduce ZBP1 activation by editing Z-RNA structures
• Nucleic acid homeostasis: Improving cytoplasmic DNA/RNA clearance to reduce ZBP1 activation

Challenges

Research Evidence

Key Studies

Animal Models

• ZBP1 knockout mice: Viable and fertile; increased susceptibility to certain viral infections but protected from some inflammatory conditions
• ZBP1-deficient ALS/FTD models: Crossing ZBP1 knockout with TDP-43 models reduces neuroinflammation and delays disease onset
• ZBP1-overexpressing mice: Show increased neuroinflammation and accelerated neurodegeneration in AD and PD models

Mermaid Diagram: ZBP1 in Alzheimer's Disease Pathogenesis

See Also

• [NLRP3 Inflammasome](/entities/nlrp3-inflammasome)
• [Necroptosis](/entities/necroptosis)
• [Neuroinflammation](/entities/neuroinflammation)
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [Amyloid-beta](/proteins/amyloid-beta)
• [Alpha-synuclein](/proteins/alpha-synuclein)
• [Microglia and Neuroinflammation](/cell-types/microglia-neuroinflammation)
• [PANoptosis](/entities/panoptosis)
• [ADAR1 and RNA Editing](/entities/adar1)

External Links

• [NCBI Gene: ZBP1](https://www.ncbi.nlm.nih.gov/gene/23073)
• [UniProt: Q9H171](https://www.uniprot.org/uniprot/Q9H171)
• [Ensembl: ZBP1](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185730)
• [Allen Brain Atlas: ZBP1 expression](https://human.brain-map.org/gene/show?gene_id=ENSG00000185730)
• [PubMed: ZBP1 neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=ZBP1+neurodegeneration+Alzheimer+Parkinson+ALS)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving ZBP1 (Z-DNA Binding Protein 1) discovered through SciDEX knowledge graph analysis: